THE CLINICAL TRIAL
The YELLOWSTONE Program is a suite of four phase 3, randomized, double-blind, placebo-controlled, multi-center studies that are evaluating the efficacy and safety of ozanimod, an investigational oral medication being studied for individuals with moderately to severely active Crohn’s disease. Ozanimod is an oral medication, not a biologic, injection or infusion. In the YELLOWSTONE PROGRAM, the investigational medication will be taken once daily. Ozanimod is also being studied for the treatment of multiple sclerosis.
A series of Phase 3 clinical trials evaluating ozanimod for people with moderately to severely active Crohn’s disease
